About Us

Enhancing Vision for Life

WHO WE ARE

We are MediPrint™ Ophthalmics

An emerging San Diego-based clinical stage eye care pharmaceutical company developing and commercializing a proprietary ocular drug delivery portfolio focused on glaucoma, dry eye and ocular allergy initially.

We are using our proprietary MediPrint™ process to develop, clinically test and commercialize drug-eluting, comfort-enhancing contact lenses to treat millions of contact lens wearers worldwide, without the use of eye drops.

We plan to address a variety of eye care unmet needs, all with extensive market opportunities.

We aim to develop and commercialize a deep product pipeline, supported by strong intellectual property, with a highly experienced and successful execution team.

Our Mission

Our goal is to change the standard of care for successfully delivering ocular drugs to the eye non-invasively. We will use our patented MediPrint™ process to offer a unique value proposition for patients, eye care professionals, strategic partners and payers.

Our Vision

Enhancing vision for life.

Executive Summary

Clinical Stage Eye Care Pharmaceutical Company Focused on Helping Protect Sight

1
Compelling Unmet Need

40M+ Soft Contact Lens Wearers in the United States

2
Pipeline Established – Strong I.P.

Glaucoma, Dry Eye, Comfort, Allergy, …

3
SIGHT-1 Phase 2a Clinical Completed

Glaucoma, five patients, safety endpoints

4
Execution Team Secured
5
Clear Path to Exit

Phase 3 data in 18 months.

Combining our SIGHT-1 first in-human clinical study results with our initial external round funding success positions us to continue advancing key assets in our pipeline to help protect sight for patients suffering from conceivably disabling eye diseases and conditions.

Dan Myers – CEO